GSK plc / Bellus Health Inc.

Refractory Chronic Cough (P2X3 receptor antagonist)

2 US cases/yr · $4.0B Projected peak global market for RCC therapeutics (analyst consensus, 2030+)

Disease Overview

Refractory chronic cough (RCC) is defined as cough persisting more than 8 weeks despite adequate treatment of underlying conditions (asthma, GERD, upper-airway cough syndrome, ACE inhibitors). Global prevalence of chronic cough is approximately 5-10% of adults, with refractory/unexplained chronic cough affecting approximately 2-4 million US adults and 5-10 million globally. The condition is more common in women and peaks in the 6th-7th decade of life. Cough hypersensitivity is driven in part by sensitized airway vagal afferent C-fibers expressing the P2X3 purinergic receptor, which responds to extracellular ATP released by airway epithelium during inflammation or mechanical stress. RCC produces substantial morbidity: urinary incontinence, syncope, rib fractures, exhaustion, social isolation, and depression. There is no FDA-approved specific therapy: current off-label options (gabapentin, pregabalin, low-dose morphine, speech pathology) have modest benefit and significant side-effect burden. Merck's gefapixant (Lyfnua, P2X3 antagonist) was rejected by FDA in January 2022 and again in December 2023 over efficacy concerns despite EMA approval, leaving the US market open. Camlipixant enters as a more-selective P2X3 antagonist (minimal P2X2/3 activity) designed to avoid the dysgeusia (taste disturbance) that limited gefapixant's utility.

Competitive Landscape

Refractory chronic cough has no FDA-approved therapy, making P2X3 receptor antagonists the first potential specific-mechanism entrants. Merck's gefapixant (Lyfnua, first-generation pan-P2X3/P2X2-P2X3 antagonist) was approved in EU (2023) and Japan but received two FDA Complete Response Letters (January 2022 and December 2023) citing efficacy concerns vs placebo in COUGH-1 and COUGH-2 trials; dysgeusia was reported in up to 58% of patients, producing high discontinuation. Bayer's eliapixant (P2X3-selective) was discontinued across all indications (RCC, endometriosis, overactive bladder, diabetic neuropathic pain) in 2022-2023 following hepatotoxicity signals. Shionogi's sivopixant (P2X3-selective) showed inconsistent data in Phase 2 and has been deprioritized. Merck's MK-8189 is a next-gen P2X3 in early development. Alternative mechanisms in RCC include: NMDA antagonists (memantine, limited), TRPV1 antagonists (xiflapiprant XCP-542, Axalbion), sodium channel blockers (nociceptor-selective NaV1.7/1.8 programs), and nerve growth factor (NGF) antibodies. Camlipixant, as the last remaining major-pharma-backed P2X3 candidate after gefapixant's FDA setbacks and eliapixant's discontinuation, is positioned as the sole path to the first US FDA-approved RCC therapy. Subsequent development has been challenging: GSK reported Phase 3 CALM-1 and CALM-2 efficacy shortfalls in December 2024, putting the program's future in question.